Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Public ClinicalTrials.gov record NCT01790295. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Study identification
- NCT ID
- NCT01790295
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- John Mascarenhas
- Other
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Interventions
- Ruxolitinib Pre- Hematopoietic cell transplantation (HCT) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2013
- Primary completion
- Oct 25, 2017
- Completion
- Oct 25, 2017
- Last update posted
- Mar 19, 2019
2013 – 2017
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory Hospital | Atlanta | Georgia | 30322 | — |
| Northwestern University, Robert h. Lurie Comprehensive Cancer Center | Chicago | Illinois | 60611 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27103 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01790295, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01790295 live on ClinicalTrials.gov.